Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Drugs Outcomes Research and Policies

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1639032

Mirabegron for intramural ureteral stones with vesical irritability: a prospective study

Provisionally accepted
Mengjun  DaiMengjun DaiYuhang  SheYuhang SheHao  WangHao Wang*
  • The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China

The final, formatted version of the article will be published soon.

Objective To assess the efficacy of mirabegron in patients with intramural ureteral stones (6-10 mm).We prospectively randomized 92 patients with intramural ureteral stones into two groups. Patients in the mirabegron group received 50 mg of mirabegron daily, while those in the tamsulosin group received 0.4 mg tamsulosin daily. All patients were required to use the Urinary Sensation Scale (USS) to assess the urinary urgency and the Visual Analog Scale (VAS) to assess pain. Patients were followed until stone expulsion or for up to 4 weeks. Results all of 80 patients were included in this study. 41 patients in mirabegron group and 39 patients in tamsulosin group as control. The average expulsion time was shorter in mirabegron group than in tamsulosin group (8.4 ± 2.9 vs. 11.2 ± 3.1 days, P< 0.0001).The stone expulsion rate (SER) was higher in mirabegron group than in tamsulosin group on 1 and 2 weeks (36.6% vs. 15.4%, P=0.031 and 75.6% vs. 43.6%, P=0.004).However, the SER on 4 weeks had no statistical difference between two groups (P > 0.05). Post-treatment VAS and USS scores were lower in mirabegron group than tamsulosin group (P < 0.05).Mirabegron not only accelerates the expulsion of intramural ureteral stones but also relieves renal colic and vesical irritability.

Keywords: Adrenergic beta-3 Receptor Agonists, Mirabegron, overactive bladder, Ureteral Calculi, Urinary tract symptoms

Received: 01 Jun 2025; Accepted: 04 Aug 2025.

Copyright: © 2025 Dai, She and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hao Wang, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.